2024-515218-42-00招募中1 期
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Yaron Raiter
Scientific
GE Healthcare Limited
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies2024-514777-22-00Invox Pharma Limited113
招募中
1 期
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).2024-519639-40-00One-carbon Therapeutics AB33
招募中
1 期
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers2023-503892-83-00Vivet Therapeutics35
招募中
1 期
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers2025-522402-21-00Kupando GmbH21
招募中
1 期
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58